NCT05489939View on ClinicalTrials.gov

Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China

CompletedOBSERVATIONAL
Enrollment

3,600

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Pain
Interventions
DRUG

The compound methyl salicylate liniment

The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.

All Listed Sponsors
lead

Xiangya Hospital of Central South University

OTHER

NCT05489939 - Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China | Biotech Hunter | Biotech Hunter